Clinical Trial Update: Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical Study [Phase 2]

View source ↗

Summary

A Phase 2, single-center randomized exploratory trial comparing neoadjuvant Cadonilimab versus chemotherapy with a PD-1 inhibitor in resectable non-small cell l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cadonilimab

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: Resectable Non-small Cell Lung Cancer, Bispecific Antibody | Phase 2 | Status: NOT_YET_RECRUITING